// App-Quantinova.ai

2190 : Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial

Researchers

Presenter

  • Uwe Platzbecker

Principal Investigators

  • Yiming Zhu

  • Xianwei Ha

  • Alberto Risueo

  • Esther Chan

  • George Zhang

  • Diana R. Dunshee

  • Melih Acar

  • Jeevan K. Shetty

  • Rodrigo Ito

  • Kyle MacBeth

  • Valeria Santini

  • Maciej W. Garbowski

  • Pierre Fenaux

  • Martin Schwickart

Medical Centers

  • Dept. Hematology and Cell Therapy,University Hospital Leipzig,Leipzig,Germania

  • Bristol-Myers Sqiubb, Princeton, NJ

  • BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol Myers Squibb Company, Seville, Spain

  • Formerly Bristol Myers Squibb, Princeton, NJ

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

  • Department of Haematological Medicine, King's College London, London, United Kingdom

  • Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7,Paris,France

Locations

  • Germany

  • United States

  • Spain

  • Switzerland

  • Italy

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

Biomarkers

  • TIMP Metallopeptidase Inhibitor 1

Drug/Treatment

  • Erythropoietin

  • luspatercept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved